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Coronary artery bypass graft surgery (CABG),
developed in the late 1960s by Favaloro and using
saphenous vein grafts dramatically changes the treatment
and the prognosis of patients with ischemic coronary artery
disease.
The aim of the surgical procedure is to improve patients’
quality of life alleviating anginal symptoms and restore
physical activity, as well as increasing survival in certain
groups of patients, especially in those at higher risk.
However, inherent factors to both procedure and basal
disease affect and even suppress the long-term benefits
provided by coronary artery bypass graft surgery. Among
these factors, the venous graft degeneration is yet one of
the greatest drawbacks.
The coronary artery bypass graft surgery success is, to
a great extent, related to the type and quality of the graft
employed. However, this continues to be our dilemma, once
the only graft which has been shown excellent long-term
outcomes and considered to be the gold standard in
coronary artery bypass graft surgery is the pediculated left
internal thoracic artery, when it is anastomosed to the
anterior descending artery.
Nevertheless, the complete myocardial revascularization
is the goal to be achieved, treating all severely stenosed
coronary arteries causing ischemia, assuring the remission
of symptoms and increasing survival. Thus, the use of
saphenous vein grafts is still vital to accomplish this goal.
Moreover, up to the present time, there is no demonstration
of the superiority of arterial grafts (except the internal
thoracic artery grafts) over the saphenous vein grafts.
Techniques and strategies to better preserve structurally
and functionally the saphenous vein could safely
contribute to a better outcome, once the increased patency
grafts correlates to an increased survival in the long-term.
The superior outcomes achieved by means of the
internal thoracic artery are due partly to the scrupulous
caution devoted by the surgeon to the dissection and the
minimal surgical trauma of this conduit, thus avoiding
traumas that could jeopardize its patency. However, this
same caution is not addressed to the saphenous vein graft,
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which often undergoes wounds and injuries during its
dissection, such as tractions and sprains leading to
structural integrity alteration, endothelial lesion, platelet
deposition, and induction and acceleration of
atherosclerotic process.
With the success of internal thoracic artery grafts
attaining excellent patency on the long-term and the
demonstration of poor outcomes of venous grafts, from
the early 1980s on, there has been an intensive search for
other types of arterial grafts to be concurrently used with
one or both internal coronary arteries and, therefore, to
achieve a complete revascularization of the myocardium.
The right gastro-omental (gastro-epiploic) artery and
the inferior epigastric artery, introduced in the early 1990s
by Suma et al. and Puig et al., respectively, did not displayed
late satisfactory and comparable outcomes with the internal
thoracic artery [1]; currently, these vessels are used only in
special cases.
The radial artery proposed by Carpentier et al. in the
early 1970s, which was shortly after abandoned, currently,
has been widely used by cardiac surgeons around the
world. There are several studies designed to convince us
that the radial artery is a graft of quality when it is used in
selected cases [2,3], even though randomized prospective
studies are needed to perform a better analysis and
discernment of this conduit.
Regarding synthetic grafts, up to the present none of
them are capable of replacing autologous vascular grafts
with the same efficacy.
Therefore, there is no question about that the saphenous
vein continues to be a necessary and crucial graft for surgical
myocardial revascularization. Notwithstanding, in order to
keep being used as a conduit in this type of surgery, the
three most important pathological alterations causing failure
and decrease of patency (thrombosis, intimal hyperplasia,
and atherosclerosis [4]) have to be attenuated, delayed, or
prevented.
Thrombosis is the main mechanism responsible for the
early occlusion of the saphenous vein grafts, which occurs
in 3% to 12% of the patients in the first week
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postoperatively. The injury to the vein wall, usually during
its removal in surgery, stimulates the activation of the
coagulation cascade system, resulting in thrombosis
formation.
Intima hyperplasia is recognized as the leading cause
of venous graft failure in the middle-term (2 to 24 months).
Intimal hyperplasia is represented by an increase in number
of normal smooth muscle cells in the vein wall that
afterwards migrate from the tunica media to the tunica
intima, resulting in a stricture of the lumen of the vein. In
venous grafts, this is followed by an increased deposition
of cell matrix. Despite the efforts to reduce intimal
hyperplasia and its clinical outcomes, the impact of
hyperplasia regarding the setting of vascular interventions
is relevant, once it forms the substrate to the development
of atherosclerosis, which is the end-stage of the graft
occlusion process.
The recidivation of myocardial ischemia symptoms
caused by the atherosclerosis of venous graft is not
usually noticed before 3 years of surgery. The development
of atherosclerosis in native arteries requires a 50- to 60-
year period, whereas in the venous grafts it takes only 5 to
10 years. One of the basic causes of the accelerated status
of the disease in venous grafts is injury and cellular
dysfunction triggered during surgical management.
Additionally, atherosclerotic plaques build up within the
venous grafts present high numbers of inflammatory and
spongy cells, as well as other morphological marked
differences when compared to the arteries [4,5].
CURRENT STRATEGIES TO REDUCE VENOUS
GRAFT FAILURE
Pharmacological agents
Several pharmacological interventions have been
introduced in an attempt to improve the vein patency. The
use of statins postoperatively along with antiplatelet agents
is already an established strategy to reduce occlusion of
the saphenous veins grafts. Recently, a clinical
investigation has shown that the use of lovastatin
significantly reduces the occlusion rate of the coronary
artery saphenous vein bypass grafts [6].
Aspirin increases vein patency up to one year after
surgery, when compared to placebo. However, after the first
year, the benefit of aspirin action disappears, suggesting
that its primary effect is to reduce early thrombosis [7].
There are evidences that the concentration of the
enzyme nitric oxide synthase (NO synthase) is reduced in
areas of vascular injury and that the nitric oxide (NO) is
involved in graft failure. Particularly, vasospasm and
thrombotic occlusion can be the result of a decreased NO
activity in the venous graft. NO prevents platelet and
leukocytic adhesion, inhibits proliferation of smooth muscle
of the vein wall, and has antioxidant activity. Nitric oxide
donor drugs causing vasodilation and inhibition of platelet
deposition in the saphenous vein, such as S-
nitrosoglutathione, have been investigated [8]. Substances
reducing neointimal hyperplasia are also being studied as
a potential pharmacological astrategy to prevent the
saphenous vein occlusion graft. Thapsigargin has been
evaluated in an attempt to inhibit the neointimal formation
in saphenous vein grafts, once it acts increasing intracellular
sodium concentration and regulating migration and
proliferation of smooth muscle cells [9].
Gene therapy
The fast advances in molecular biology in recent years
lead to the development of gene therapy techniques aiming
at identifying the methods to reduce venous graft
hyperplasia [10,11]. Clinical trials of the gene therapy use
are expected as a potential application in clinical practice in
order to improve patency of saphenous vein grafts. The
three first processes involved in the development of graft
failure, that is, early thrombosis, intimal hyperplasia, and
accelerated atherosclerosis, all represent potential targets
to agents with antithrombotic, antiproliferative,
antimigratory, pro-apoptotic, and antiinflammatory
properties.
However, a recent large randomized multicenter study,
the PREVENT IV [11], that has analyzed more than 3000
patients undergoing coronary artery bypass grafting
surgery, did not show benefit from the gene therapy
application. The occlusion rate of saphenous vein grafts
was > 40% in the angiographic exam performed between 12
and 18 months, both the group receiving treatment and
group control, thus raising the hypothesis that vein minimal
surgical trauma, wound, and injuries before its implantation
are, unquestionably, the triggering mechanisms of the
processes leading to the loss of patency.
External stents
Experimentally, external stents, both synthetic and
biodegradable, have decreased the formation of neointima
in porcine veins, which were interposed in carotid arteries.
Mehta et al. [12] demonstrated that both the Dacron
synthetic graft and the biodegradable polyglactin grafts
decrease the thickening of tunicae media and intima.
Perivenous support reduces endothelial lesion and other
alterations in studies carried out with human veins perfused
with blood (in vitro) [13]. However, the randomized study
performed in patients receiving saphenous vein grafts
treated with external polyester stent showed that all veins
were occluded 6 months after surgery [14].
Synthetic grafts
The most tested and used artificial grafts in
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cardiovascular surgery were both Dacron and
polytetrafluoroethylene (PTFE) grafts. Studies in patients
with recurrent myocardial revascularizations who have
received such grafts due to the lack of autologous grafts
showed disappointing outcomes, mainly because of the
thrombogenicity and subsequent intimal hyperplasia,
especially in regions of anastomoses. The patency of
polytetrafluoroethylene (PTFE) grafts in coronary artery
bypass grafting surgery is 14% at 45 months [15].
Attempts of endothelialisation of artificial grafts by
means of seeding of the graft lumen with endothelial cells
also did not improve the outcomes, resulting in a patency
of only 60% at 4 years [15].
Tissue engineering
This procedure involves the development of grafts
constructed with a mixture of vascular smooth muscle,
collagen, and endothelial cells [15], requiring several
weeks of graft preparation and, thus, it cannot be used in
emergency surgery. This method was not yet clinically
assessed; its long-term efficacy and patency rate remain
unknown. It has been suggested that this method of
vascular tissue engineering will not be accepted until
superior outcomes, or those comparable to autologous
grafts have been demonstrated in clinical trials. At
present, the combination of endothelial cells implantation
with gene therapy vascular endothelial nitric oxide
synthase (eNOS) seems to present a great potential to be
used in synthetic grafts. 
Refining the paradigm: the technique of vein
preparation
With the disappointing outcomes provided by the
alternative grafting strategies discussed above, there is
no doubt about that all efforts should be driven in order
to avoid injury of the vein wall during its preparation and,
consequently, improving the outcomes. Several studies
demonstrated that the injury occurring during vein
preparation is one of the major factors of its failure when
it is used as a graft in coronary artery bypass graft surgery
[16]. It is interesting to notice that the vein continues to
be prepared with the same conventional technique
formally approved since the beginnings of coronary artery
bypass graft surgery, over 40 years ago, that is, the vein
is denuded and distended before being implanted. This
could have been a critical failure and might have entailed
its relative failure in face of the internal thoracic artery
grafts.
It has been acknowledged for many years that the high
pressure applied to distend the saphenous vein to the effect
of reversing the spasm during its preparation and checking
for leaks is the main cause of loss of endothelial layer and
medial damage [17]. This is the main triggering factor of
pathological events, which are responsible for grafting
occlusion.
Recently, the introduction of a novel technique of the
saphenous vein preparation, the technique “no-touch”,
in which the vein is harvested with a pedicle (1 cm) of
surrounding fatty tissue and minimal surgical trauma,
represents an advance in the maintenance of graft
physiological and structural integrity [18]. A randomized
study comparing both techniques – “no-touch” vs
conventional – has shown a significant vein patency
improvement, both in the short-term (18 months, 89%
conventional vs 95% no-touch; p<0.0025) and in the long-
term (8.5 years, 76% conventional vs 90% no-touch;
p<0.01) [19,20].
Some mechanisms have been proposed to explain the
success of this technique. First, in the no-touch technique,
the occurrence of vein spasm can be avoided or reduced,
thus, the vein in this particular case does not to be dilated.
The fatty tissue can function as an external biological
stent, providing support against the detrimental effect of
arterial pressure on the ascending aorta over the vein wall.
Also, fatty tissue protects against injury caused by direct
manipulating of the vein wall with surgical instruments.
Recently, a significant number of adipose-derived
peptides have been identified, among them the adipocyte-
derived relaxing factor secreted into the plasma, which
plays an important vascular regulation and hemostasis
role [21]. Particularly, perivascular fat is an important source
of NO, contributing to improve the patency of the vein
prepared using intact fatty tissues. Vein segments
harvested from patients undergoing coronary artery
bypass graft surgery have demonstrated that the
perivascular tissue-derived enzyme eNOS plays a crucial
role in improving the patency of the saphenous vein graft
prepared atraumatically [22]. The denudation of
perivascular fat, used in the conventional technique, can
substantially reduce eNOS levels, thus contributing to
the worsening of the saphenous vein patency.
It has been demonstrated that the vein endothelium
treated with the no-touch technique remains intact [23],
preserving the enzyme eNOS, which represents an additional
mechanism to improve patency [23.24]. Besides preserving
the endothelium, it has been suggested that the protection
of the “vasa vasorum” network plays a fundamental role in
the success of this novel technique. It has been
demonstrated that this network of nourishing microvessels
penetrates deeply into the tunica media, ending up into the
vein lumen, thus providing a retrograde filling of the vasa
vasorum [23]. The preservation of the vasa vasorum network
aims at providing the restoration of blood flow through the
vein wall, thus reducing ischemic injury. These outcomes
suggest that the preservation of the tissue surrounding
the vein by the no-touch technique, including perivascular
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fat, not only provides structural support and minimizes
surgical trauma, but also plays an important role in
modulating vascular tonus, preserving the endothelial
function, and reducing neointimal thickening [22]. A matter
of great concern to this evidence is the previous study
published by Gao et al. [25] that reported the potential of
perivascular adipose tissue preservation in the internal
thoracic artery grafts, reducing the occurrence of
vasospasm of the graft vessels.
CONCLUSION
Despite all the advances verified in the last decades in
coronary artery bypass graft surgery, the use of the
saphenous vein graft continues to be critical in achieving a
complete coronary artery bypass graft goal in the majority
of the patients, but venous graft failure still represents a
severe issue that needs to be solved.
Most of the  current breakthrough strategies used to
improve the saphenous vein graft outcomes, both in
experimental and clinical studies, have been attempting to
fix the effects of surgical trauma by means of replacement,
restoration, or inhibition of the factors released by vascular
trauma during vein preparation.
Notwithstanding, there is no question about the better
approach to prevent vascular injury instead of trying to
repair it after its occurrence, which should be started at the
surgery room using atraumatic surgical techniques to graft
preparation.
Therefore, the use of no-touch technique associated
with up-to-date pharmacological strategies could
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